A central question in manganese neurotoxicity concerns mitochondrial dysfunction leading to cerebral energy failure. To obtain insight into the underlying mechanism(s), the authors investigated cell-specific pathways of [1-13 C]glucose metabolism by high-resolution multinuclear NMR-spectroscopy. Five-day treatment of neurons with 100-mol/L MnCl 2 led to 50% and 70% decreases of ATP/ADP and phosphocreatine-creatine ratios, respectively. An impaired flux of [1-13 C]glucose through pyruvate dehydrogenase, which was associated with Krebs cycle inhibition and hence depletion of [4-13 C]glutamate, [2-13 C]GABA, and [ 13 C]glutathione, hindered the ability of neurons to compensate for mitochondrial dysfunction by oxidative glucose metabolism and further aggravated neuronal energy failure. Stimulated glycolysis and oxidative glucose metabolism protected astrocytes against energy failure and oxidative stress, leading to twofold increased de novo synthesis of [3-13 C]lactate and fourfold elevated [4-13 C]glutamate and [ 13 C]glutathione levels. Manganese, however, inhibited the synthesis and release of glutamine. Comparative NMR data obtained from cocultures showed disturbed astrocytic function and a failure of astrocytes to provide neurons with substrates for energy and neurotransmitter metabolism, leading to deterioration of neuronal antioxidant capacity (decreased glutathione levels) and energy metabolism. The results suggest that, concomitant to impaired neuronal glucose oxidation, changes in astrocytic metabolism may cause a loss of intercellular homeostatic equilibrium, contributing to neuronal dysfunction in manganese neurotoxicity.
Manganese, required for the activity of many enzymes, is essential for normal physiologic functioning (Underwood, 1981) . Chronic exposure to manganese, however, leads to neurotoxicity (manganism) and is characterized by neuropsychiatric symptomatology that often resembles Parkinson disease (Huang et al., 1989; Mena et al., 1967) . Neuropathologic changes are manifested mainly in the globus pallidus and include neuronal loss, gliosis, and Alzheimer type II astrocytosis (Pentschew et al., 1963; Yamada et al., 1986) . The primary basis for manganese neurotoxicity remains unclear, but changes of both astrocytic and neuronal integrity indicate that several biochemical events may be involved. The accumulation of manganese in mitochondria (Wedler et al., 1989) suggests the possibility of mitochondrial derangements. As mitochondrial function is tightly coupled to cellular energy production, compromised brain energy metabolism leading to decreased oxidative phosphorylation may be a central feature of manganese neurotoxicity.
Astrocytes sequester manganese (Aschner et al., 1992; Tholey et al., 1990; Wedler et al., 1989) and are considered as the likely initial targets of manganese neurotoxicity (Henriksson and Tjalve 2000; Spranger et al., 1998) . The glial localization of pyruvate carboxylase (PC), the key anaplerotic enzyme in the brain (Shank et al., 1985) , and glutamine synthetase (GS) (Norenberg and Martinez-Hernandez, 1979) , suggest an important role of these cells in brain energy metabolism. In this context, changes in astrocyte metabolism may either modify primary neuronal injury or induce secondarily neuronal dysfunction. In contrast to other organs, brain energy metabolism depends almost exclusively on the oxidation of glucose (Gjedde and Marrett, 2001) . Via tricarboxylic acid (TCA) cycle activity, glucose metabolism also leads to the biosynthesis of neurotransmitters such as glutamate, aspartate, and ␥-aminobutyric acid (GABA). The metabolic activities of the energy-producing pathways are under strict coordinated control and involve glycolysis, the TCA cycle, oxidative phosphorylation, and the pentose-phosphate pathway. So far, however, no data are available from simultaneous studies to correlate the mechanisms that link manganese-induced mitochondrial dysfunction and energy failure with glucose metabolism. The use of stable isotope-labeled precursors is a common technique used to study biochemical pathways. In particular, 13 C-labeled substrates and the high chemical specificity of 13 C-NMR permits the identification of 13 C label in specific positions of given compounds and allows for the simultaneous calculation of substrate concentrations and multiple inter-and intracellular metabolic fluxes in the intact brain and cell cultures in a comprehensive manner, which is not possible with classic studies using 14 C-labeled isotopes (Bachelard and Badar-Goffer, 1993; Cruz and Cerdan, 1999; Gruetter et al., 1994) .
In the present study, we applied multinuclear NMR spectroscopy and an in vitro approach using primary astrocytes, neurons, and their cocultures to analyze metabolic pathways coupled to oxidative phosphorylation by simultaneous determination of high-energy phosphates, cell-specific de novo synthesis of metabolites derived from anaerobic and oxidative [1- 13 C] glucose metabolism, and the involvement of intercellular trafficking after manganese treatment.
MATERIALS AND METHODS

Cell cultures
Primary cell cultures of cortical astrocytes, cortical neurons, and cocultures of both cell types were obtained as described previously (Booher and Sensenbrenner, 1972; Zwingmann et al., 2000) . Astrocytes were prepared from the brains of 1-or 2-day-old Sprague-Dawley rats and cultured in Dulbecco modified Eagle medium (DMEM) containing 10% fetal calf serum for 3 weeks. Neurons were prepared from 16-to 18-day-old rat embryos according to Richter-Landsberg (1988) and cultured in basal medium Eagle containing 0.5% fetal calf serum (to avoid astrocytic proliferation). For cocultures, astrocytes were first cultivated in DMEM until reaching confluence; thereafter, neuronal cells were added and cultivated as described for neurons. Approximately 10 7 to 10 8 cells were used for each NMR experiment. In cocultures, the ratio of astrocytes to neurons was found to be 4:6. All cultures were kept in an incubator with a humidified atmosphere of 5% CO 2 at 37°C. Astroglial and neuronal cultures were characterized by GFAP immunoreactivity and antineurofilament antibodies, respectively. The purity of the individual cells was found to be >95% for primary astrocytes and >90% for primary neurons.
Incubation and preparation of cell extracts
Confluent cell cultures were incubated every 24 h with fresh media containing 100-mol/L MnCl 2 on 5 consecutive days. During the last 12 h, control cultures and manganese-treated cells were incubated for 12 h with DMEM containing 5-mmol/L [1-13 C]glucose (Cambridge Isotope Laboratories, Andover, MA, U.S.A.). After removal of the incubation media (lyophilized for subsequent NMR measurements), the cells were extracted with perchloric acid (PCA) as described previously (Zwingmann et al., 2000) . Because of the paramagnetic effect of manganese on T 1 relaxation times, di-and trivalent cations were complexed by incubation of the supernatant with iminodiacetic acid (Chelex 100; Sigma, St. Louis, MO, U.S.A.) for 20 minutes. After removing of the chelating resin by filtration, the supernatants were lyophilized.
Biochemical analysis
The enzymatic assays (determination of lactate concentrations) were performed according to the supplier's instructions (Roche Molecular Biochemicals, Mannheim, Germany) with measurement of the UV/VIS absorption of NADH at 340 nm. The protein content was quantified according to the Biuret reaction (Goa, 1953) using bovine serum albumin as a standard and VIS absorption at 540 nm. All biochemical assays were adapted for use in 96-well microtiter ELISA plates. Samples were measured in four concentrations in the plate, each with four replicates.
Nuclear magnetic resonance spectroscopy
The lyophilized samples were redissolved in 0.5 to 0.6 mL deuterium oxide (D 2 O; Merck, Darmstadt, Germany) and centrifuged. Before the NMR analysis, the samples were neutralized with DCl and NaOH to allow unique chemical shift assignments and to prevent glutamine-carbamate formation in the media. 1 H-, 13 C-and 31 P-NMR spectra were recorded on Bruker spectrometers DRX600 or AMX360/AM 360 (operating for 1 H-NMR at frequencies of 600 MHz or 360 MHz, for 13 C-NMR at 150.9 MHz or 90.5 MHz, and for 31 P-NMR at 145.7 MHz). 1 H-NMR spectra were recorded with a 5-mm H,C,N inverse triple-resonance probe using 200 to 400 accumulations, a flip angle of 40°, a repetition time of 15 seconds, a spectral width of 7,183 Hz (DRX 600) or 3,623 Hz (AM/AMX 360), a data size of 16 K, and zero filling to 32 K. Chemical shifts were referenced to lactate (1.33 ppm). 13 C-NMR spectra were recorded with a 5-mm 1 H/ 13 C dual probe using 15,000 to 20,000 accumulations, a repetition time of 2.5 seconds, a flip angle of 27°, composite pulse decoupling with WALTZ-16, a spectral width of 47,619 Hz (DRX 600) or 20,833 Hz (AM/AMX 360), a data size of 32 K (16 K), and zero filling to 64 K (32 K). Chemical shifts were referenced to lactate (21.3 ppm). 31 P-NMR spectra were recorded with a 5-mm HX probe using 5,000 to 8,000 accumulations, a flip angle of 80°, a repetition time of 3.5 seconds, a spectral width of 5,155 Hz, composite pulse decoupling with WALTZ-16, a data size of 16 K, and zero filling to 32 K. The resonance of phosphocreatine (−2.33 ppm) was used as internal shift reference.
Quantification of metabolite concentrations
The concentrations of lactate were determined enzymatically (see Biochemical analysis). The pool sizes of other metabolites were determined from fully relaxed 1 H-NMR spectra using the known lactate concentration as internal standard or using (trimethylsilyl)propionic-2,2,3,3,d 4 -acid (TSP) as external standard. 31 P-NMR spectra were analyzed with reference to the phosphocreatine concentrations, calculated from 1 H-NMR spectra (nmol/mg protein for cell extracts, mol/mg protein for media).
Calculation of fractional 13 C-enrichments and amounts of 13 C-labeled metabolites
The 13 C-enrichments in C-3 of lactate were determined by the heteronuclear spin-coupling pattern in 1 H-NMR spectra as follows: 13 13 C. 13 C-enrichments in individual carbons of amino acids are derived from 13 C-NMR spectra using the known 13 C-enrichment in lactate as described previously (Zwingmann et al., 2000) :
where A Met represents 13 C carbon peak area of the metabolite, A n.a. its natural abundance signal intensity, and 1.1 is the percentage factor of the 13 C-isotope. The 13 C signal intensities were corrected for nuclear Overhauser enhancement effects. The absolute amount of 13 C in specified carbon positions (nmol/mg protein) is the product of the pool size times the fractional 13 C-enrichment. Due to overlapping signals, glutathione and citrate cannot be integrated reliably by 1 H-NMR, and changes in 13 C-label incorporation were deduced from relative signal intensities in 13 C-NMR spectra (normalized by the corresponding signal areas obtained after incubation of cells with unlabeled glucose).
13
C-isotopomer analysis
Theoretical labeling of metabolites from [1-13 C]glucose. After incubation of cells with [1-13 C]glucose, its metabolites are labeled in different carbon positions, depending on the relative contribution of the enzymatic pathways ( Fig. 1 ; Zwingmann et al., 2000) . Briefly, via the glycolytic pathway, [1- 13 C] glucose is transformed to [3-13 C]pyruvate, [3-13 C]alanine, and [3-13 C]lactate. [3-13 C]Pyruvate may enter the TCA cycle via the anaplerotic pathway (PC or malic enzyme) or the oxidative pathway (pyruvate dehydrogenase, PDH). Via PC, glutamate and glutamine are labeled at C-2 (and at C-3 after equilibration of oxaloacetate with fumarate). In the oxidative pathway, pyruvate enters the cycle as [2-13 C]acetyl-CoA, and glutamate and glutamine are monolabeled at C-4. During the second TCA cycle turn, glutamate and glutamine are monolabeled after condensation of 13 C-labeled oxaloacetate with unlabeled acetyl-CoA, but doubly labeled ([3,4-13 C]-and [2,4-13 C]) after condensation with [2-13 C]acetyl-CoA. The order of labeled carbons is reversed in GABA (i.e., the labels in [2(4)- 13 C]glutamate end up in [4(2)-13 C]GABA). In 13 C-NMR spectra, monolabeled and doubly labeled isotopomers are observed as singlets and doublets, respectively.
Contribution of pyruvate carboxylase versus pyruvate dehydrogenase. The relative contribution of the anaplerotic pathway was estimated by the ratio of C2/C4 in glutamate and glutamine.
Scrambling of the label in the TCA cycle. As PDH activity leads to [4- 13 C] glutamate and double-labeled [3,4-13 C]glutamate during the first and the second TCA cycle turn, respectively, the labeling ratios of mono/double C-4 in glutamate reflect the number of turns that [2- 13 C] acetyl-CoA has made in the TCA cycle.
Enrichment in acetyl-CoA. If [4-13 C]2-oxoglutarate remains in the TCA cycle up to [2- 13 C] oxaloacetate and reacts with unlabeled acetyl-CoA, monolabeled glutamate C-3 will appear. Double-labeled glutamate will result if [2- 13 C] acetyl-CoA and [2- 13 C] oxaloacetate are converted into glutamate. Thus, the ratio of mono-to double-labeled glutamate C-3 reflects the 13 C-enrichment of the acetyl-CoA pool.
Statistical analysis
The NMR studies were carried out on four to six independent experiments. Data are expressed as mean ± SD values. Data from all experimental groups were analyzed and compared using ANOVA and post hoc Tukey test. Differences were considered significant when P < 0.05.
RESULTS
Cellular energy state
Analysis of 31 P-NMR spectra of PCA extracts (Fig. 2 ) depicting high-energy phosphates such as nucleoside diand triphosphates (NDPs and NTPs), in particular ADP, ATP, and PCr, showed that 5-d treatment of astrocytes with 100-mol/L MnCl 2 produced no change in NTP and PCr concentrations (Table 1) . In cultured neurons, on the other hand, NTP/NDP and PCr/creatine ratios were 51% and 28% lower compared with control values, respectively (P < 0.001; creatine was calculated from 1 H-NMR spectra), indicating a decreased energy state. When astrocytes were cocultured with neurons (astrocytes:neurons ‫ס‬ 4:6), PCr was lowered to 32% (P < 0.01), but NTP levels were unchanged. Considering the relative concentrations of PCr in astrocytes and neurons, the theoretical intermediate of PCr in the two cell types under control conditions and after manganese treatment (11.45 vs. 10.67 nmol/mg protein) showed a higher decrease of PCr in manganese-treated cocultures compared with neuron cultures (P < 0.001).
Glycolytic metabolic flux of glucose
As a measure of the glycolytic flux, the consumption of [1-13 C]glucose ([ 13 C]Glc) and the de novo synthesis of [3-13 C]lactate ([ 13 C]Lac) were calculated from 1 Hand 13 C-NMR spectra of media ( Fig. 3 ) and PCA extracts (Tables 2 and 3) .
Uptake of [1-13 C]glucose and release of [3-13 C]lactate. Table 2 shows the concentrations of extracellular [1-13 C]glucose (T ‫ס‬ 0 and 12 h) and [3-13 C]lactate (T ‫ס‬ 12 h). Under control conditions, the uptake of [ 13 C]Glc and the release of [ 13 C]Lac, which were calculated from the difference of their concentrations at T ‫ס‬ 0 and 12 h, were highest in cocultures (Table 2 ; P < 0.001 between control values in astrocytes, neurons, and cocultures). Treatment of astrocytes and cocultures with 100-mol/L manganese (5 d) increased the release of de novo synthesized [ 13 C]Lac to 215% and 155% of control values (P < 0.001), respectively, which coincided with stimulated [ 13 C]Glc uptake. In contrast, in neurons, a decrease in the consumption of [ 13 C]Glc and the release of [ 13 C]Lac to about 65% (P<0.001) of control values was observed 5 d after manganese exposure.
Intracellular [1-13 C]glucose and [3-13 C]lactate. Stimulated glycolytic flux of glucose in astrocytes after 5-d treatment with manganese was reflected also by 35% reduced intracellular [ 13 C]Glc (P < 0.001; Table 3 ). [ 13 C]Glc was metabolized almost completely when astrocytes were cocultivated with neurons (P < 0.01 compared with pure astrocytes). In contrast to astrocytes, however, intracellular [ 13 C]Lac remained unchanged in manganese-treated cocultures. In neurons, a manganeseinduced impaired glycolytic flux was associated with decreased intracellular [ 13 C]Lac (P < 0.001) in parallel to an accumulation of nonmetabolized [ 13 C]Glc to almost 300% of control.
Percentage 13 C-enrichment in lactate. To determine the selectivity of [ 13 C]Glc metabolism compared with other exogenous substrates, the percentage 13 C-enrichments in lactate was calculated from 1 H-NMR spectra (Fig. 4 ). Treatment of astrocytes with manganese resulted in no obvious alterations of 13 C-enrichments in intracellular lactate but increased selectively the release of lactate that had been synthesized de novo from [ 13 C]Glc (P < 0.05; Fig. 4B ). In neurons, the 13 C-enrichments in intra-and extracellular lactate decreased to 70% to 75% of control (P < 0.01), whereas in cocultures the 13 C-enrichment in extracellular lactate decreased to 75% of control (P < 0.01).
FIG. 1.
Metabolic fate of 13 C-label from [1-13 C]glucose. Label distribution in glycolytic and tricarboxylic acid (TCA) cycle intermediates during metabolism of [1-13 C]glucose. For label distribution in TCA cycle intermediates, only one TCA cycle turn from pyruvate to malate is considered; for glutamine, glutamate, and GABA, the label distribution after two TCA cycle turns is presented. One 13 C-label position in lactate and alanine synthesized via lactate dehydrogenase (LDH) and alanine aminotransferase (ALAT), respectively, and in TCA cycle-related metabolites synthesized through pyruvate carboxylase (PC) or pyruvate dehydrogenase (PDH) during the first TCA cycle turn. Gray circles indicate positions of the 13 C-label due to equilibration of oxaloacetate with fumarate and the 13 C-label within the second TCA cycle turn via PDH. GABA, ␥-aminobutyric acid; AAT, aspartate aminotransferase.
Concentrations of TCA cycle-related metabolites and organic osmolytes
The concentrations of amino acids were calculated from the 2.2-to 3.6-ppm region of 1 H-NMR spectra (Table 4) . Glutamine declined to 45% in cocultures of astrocytes and neurons compared with nontreated cells (P < 0.001), whereas no changes were observed in pure astrocytes or neurons. The concentration of glutamate increased in manganese-treated astrocytes and cocultures (5 d, 100 mol/L) to 180% and 170% of control, respectively (P < 0.01; not statistically significant between astrocytes and cocultures). Whereas manganese increased aspartate in astrocytes to 125% (P < 0.05), it remained unchanged in cocultures. Manganese-treated neurons manifested 30% to 35% decreased intracellular levels of glutamate and aspartate (P < 0.05). After 5-d treatment with manganese, a generalized increase of the TCA-cycle intermediate succinate to 140% to 185% of control levels (P < 0.01) was observed in the order cocultures> neurons>astrocytes (P < 0.001 neurons and cocultures vs. astrocytes). In addition, the concentrations of organic osmolytes were calculated (3.4 to 4.05 ppm). Taurine levels were increased in astrocytes to 250% of control (P < 0.001), but decreased in neurons (P < 0.05) and, in particular, in cocultures to 60% of control (P < 0.001; P < 0.01 cocultures vs. neurons). Hypotaurine, the direct precursor for taurine, and myo-inositol, an astrocytic marker molecule, were unchanged in pure astrocytes after 5-d manganese treatment, but decreased to 25% and 55% of control levels (P < 0.001) in cocultures. Figure 5 shows representative 13 C-NMR spectra obtained from extracts of cocultures of astrocytes and neurons after 12-h incubation with 5-mmol/L [1-13 C]glucose. Whereas 13 C-labeled glutamate was hardly detected in astrocytes under control conditions, 5-d exposure of astrocytes to 100-mol/L manganese led to increased synthesis of the isotopomer [4-13 C]glutamate, formed in the PDH pathway, reflected by an increased total amount and 13 C-enrichment to 400% and 220% of control, respectively (Tables 5 and 6 ). Consistent with unchanged glutamine concentrations (Table 4) , the increased glutamate synthesis was not accompanied by subsequent incorporation of 13 C-label into glutamine. When astrocytes were cocultured with neurons, manganese exposure resulted not only in stimulated PDH-mediated synthesis of [4-13 C]glutamate, but in particular in increased flux through PC leading to increased [2-13 C]glutamate and [3-13 C]aspartate synthesis (P < 0.001). Despite stimulated glutamate synthesis in cocultures, however, manganese exposure led to decreased [ 13 C]glutamine levels to 7% (C-4) and 26% (C-2) of control values (P < 0.001) ( Table 5 ). A similar observation was made from 13 C-NMR spectra of the incubation media. In control cells, the re- The concentrations of high-energy phosphates were calculated by integration of the respective signals in 31 P-NMR spectra (Fig. 2) and 1 H-NMR spectra (Cr) after 12-h incubation of astrocytes, neurons, and cocultures of both with media containing 5 mmol/L [1-13 C]glucose under control conditions or after treatment with manganese (100 mol/L MnCl 2 , 5 d). The metabolites were quantified with reference to the PCr concentration, which was calculated from 1 H-NMR spectra. Values are given as nmol/mg protein (or metabolite ratios) and represent means ± SD of four to six individual experiments. Data between all experimental groups were analyzed using ANOVA and posthoc Tukey test (*P < 0.01, †P < 0.05 compared with controls, ‡P < 0.001).
Cell-specific [1-13 C]glucose metabolism
PCr, phosphocreatine; Cr, creatine. . 1) . In manganese-treated cocultures, the 13 C-enrichment and the absolute amount of 13 C in [2- 13 C] GABA increased dramatically to almost 200% and 400% of control values, respectively. Other 13 C-enriched metabolites. Whereas treatment of astrocytes with 100-mol/L manganese resulted in a more than fourfold elevation of [ 13 C]glutathione (P < 0.001), its signal intensity was reduced to 25% and 70% of control levels in cocultures and neurons, respectively (P < 0.01; P < 0.01 between cocultures and neurons; Fig. 6 ). The conversion of [1-13 C]Glc into the TCA cycle intermediate citrate increased in astrocytes and neurons to 140% and 180%, respectively (P < 0.001), and more than 12-fold in cocultures (P < 0.001 between the individual cell types).
Oxidative (pyruvate dehydrogenase) versus anaplerotic (pyruvate carboxylase) glucose metabolism. The relative contribution of the oxidative (PDH) versus the anaplerotic (PC) pathway was calculated by the ratio of 13 C-4/ 13 C-2 in glutamate and glutamine ( Fig. 7A ). 13 C-NMR spectra of lyophilized media before and after 12-h incubation of cell cultures with media containing 5 mmol/L [1-13 C]glucose under control conditions or following treatment with manganese (100 mol/L MnCl 2 , 5 d); no unlabeled glucose was detected in 1 H-NMR spectra. Values are given as mol/mg protein or percentage of control after manganese treatment (in media based on the amounts of [1-13 C]glucose/[3-13 C]lactate, taken up from/released into the media during 12 h of incubation time) and represent means ± SD of four to six individual experiments. Data between all experimental groups were analyzed using ANOVA and post hoc Tukey test (*P<0.001; †P<0.05 compared with controls; for differences between individual cell types see text). 13 C-NMR spectra of lyophilized incubation media before and after incubation of astrocytes and neurons with media containing 5-mmol/L [1-13 C]glucose. The spectra were minimized in size to show the 13 C-signals of glucose and lactate (the major metabolite labeled with 13 C).
FIG. 3.
Under control conditions, the relative flux of label through PC was highest in astrocytes, and only marginal in neurons. The greater increase of 13 C-label incorporation into C-4 compared with C-2 of glutamate in astrocytes after manganese treatment, however, indicates a relative almost twofold activation of the oxidative pathway (PDH) (P < 0.001). In contrast, manganese treatment caused a relative decrease of oxidative Data between all experimental groups were analyzed using ANOVA and post hoc Tukey test (***P < 0.001; **P < 0.01, *P < 0.05 compared with controls; see text for differences between individual cell types). Lac, lactate; Ala, alanine; Thr, threonine. double-to mono-labeled [3-13 C]glutamate in manganese-treated astrocytes is consistent with a twofoldincreased 13 C-enrichment in acetyl-CoA (P < 0.001, Figs. 7B and 8) . The reductions of double-labeled glutamate C-3 in neurons and cocultures, in contrast, indicate decreased formation of [2-13 C]acetyl-CoA by 40% and 60%, respectively (P < 0.001). Concomitant with an increased 13 C-enrichment in acetyl-CoA in manganese-treated astrocytes, a substantial amount of the 13 C-label passed through the TCA cycle for more than one turn before glutamate was formed, as revealed by a twofold increase in the ratio of double/monolabeled glutamate C-4 (P < 0.001; Fig. 7B ). Consistent with impaired mitochondrial oxidative metabolism in neurons, manganese treatment resulted in reduced cycling ratio of [2-13 C]acetyl-CoA within the TCA cycle to 70% of control (P < 0.01), which was further decreased in cocultures (P < 0.01). The concentrations of the metabolites were calculated by integration of the respective signals in 1 H-NMR spectra after 12-h incubation of cell cultures with media containing 5 mmol/L [1-13 C]glucose under control conditions or after treatment with manganese (100 mol/L MnCl 2 , 5 d). The values are given as nmol/mg protein and represent means ± SD of four to six individual experiments. Data between all experimental groups were analyzed using ANOVA and posthoc Tukey test (*P < 0.001; †P < 0.01, ‡P < 0.05 compared with controls; for differences between individual cell types see text).
GABA, ␥‫ס‬aminobutyric acid.
Short-term effects of manganese on neuronal and glial energy metabolism.
Since manganese is a cofactor or activator for several enzymes, we investigated whether manganese directly regulates metabolic pathways in astrocytes and neurons during 12-h incubation with [1-13 C]glucose. Figure 8 shows 13 C-NMR spectra of PCA extracts obtained from astrocytes, treated for 12 h or 5 d with 100-mol/L manganese, after 12-h incubation with [1-13 C]glucose. After 12-h treatment, both astrocytes and neurons showed decreased ATP concentrations to approximately 70% of control values without changes in PCr concentrations (P < 0.01). No changes in [1-13 C]glucose uptake and metabolism (i.e., glycolytic activity and lactate synthesis), TCA cycle activity, or glutathione synthesis were observed in neurons after 12-h exposure to manganese (data not shown). After 5-d treatment, PCr decreased in neurons, and this decrease was associated with strongly impaired glucose utilization (see results under Glycolytic Metabolic Flux of Glucose). Figure 9 compares the changes induced after 12-h and 5-d manganese exposure in astrocytes (percent of control). ATP levels recovered in astrocytes, The total amounts of 13 C (nmol/mg protein) in specific carbon positions of individual tricarboxylic cycle-related amino acids labeled from [1-13 C]glucose were calculated from 13 C-NMR spectra obtained from cell extracts after 12-h incubation with media containing 5 mmol/L [1-13 C]glucose under control conditions of following treatment with manganese (Mn; 100 mol/L MnCl 2 , 5 d). Values are given as nmol/mg protein for the controls and as percentage of control after Mn treatment and represent means ± SD of four to six individual treatments. Data between all experimental groups were analyzed using ANOVA and posthoc Tukey test (*P < 0.001, †P < 0.01 compared with controls; for differences between individual cell types see text).
Gln, glutamine; Glu, glutamate; GABA, ␥-aminobutyric acid; Asp, aspartate. The percentage 13 C-enrichments in specific carbon positions of individual tricarboxylic cycle-related amino acids labeled from [1-13 C]glucose were calculated from 13 C-NMR spectra obtained from cell extracts after 12-h incubation with media containing 5 mmol/L [1-13 C]glucose under control conditions or after treatment with manganese (Mn; 100 mol/L MnCl 2 , 5 d). Values are given as percentage 13 C-enrichment for the controls and as percentage of control after Mn treatment and represent means ± SD of four to six individual experiments. Data between all experimental groups were analyzed using ANOVA and posthoc Tukey test (*P < 0.001; †P < 0.01, ‡P < 0.05 compared with controls; for differences between individual cell types see text).
Gln, glutamine; Glu, glutamate; GABA, ␥-aminobutyric acid; Asp, aspartate. also associated with a 170% increased and a 45% decreased flux of [1-13 C]glucose through PDH versus PC (ratio of 13 C-4/ 13 C-2) contributing to de novo synthesis of glutamate and glutamine, respectively. In addition, after 12-h treatment with manganese, a dramatic (10-fold compared with 5-d treatment) increase of 13 C-labeled aspartate in astrocytes is consistent with an activation of flux through PC (data not shown in Fig. 9 ). The relative flux of 13 C-label through the PC pathway contributing to glutamine synthesis from glutamate as well as glutathione and citrate synthesis decreased after 5-d compared with 12-h manganese treatment (P < 0.001; P < 0.01 compared with 5-d treat-ment; Figs. 9B and 9C ). In addition, a 75% higher ratio of double-to mono-labeled carbon C-4 in the [4-13 C]glutamate residue of glutathione compared with glutamate (data not shown) show that glutathione was synthesized subsequently to stimulated PDH activity (i.e., after the 13 C-label exceeded several TCA cycle turns).
DISCUSSION
Manganese neurotoxicity may involve mitochondrial dysfunction leading to decreased energy production. Previous studies, however, have provided little direct evidence for an altered brain energy metabolism and have FIG. 8. 13 C-NMR spectra of perchloric acid extracts obtained from astrocyte cultures after 12-h incubation with 5-mmol/L [1-13 C]glucose under control conditions and after 5-d or 12-h treatment with 100-µmol/L MnCl 2 . For peak assignments see Fig. 6 The multiple pattern of [3-13 C]glutamate and [3-13 C]glutamine is shown in the expanded plots of the respective chemical shift region (the experimental spectra are smoothed by an exponential multiplication corresponding to a line broadening of 0.5 Hz). not distinguished between the potentially different susceptibility of neural cells to manganese-induced metabolic derangements.
By means of multinuclear NMR investigations, allowing simultaneous monitoring of cellular energy state, [1-13 C]glucose metabolism and intercellular metabolic trafficking, we have shown for the first time that manganese selectively impairs neuronal glucose oxidation leading to reduced antioxidant capacity and disruption of mitochondrial energy production. Astrocytes, in contrast, increased their oxidative and anaerobic glucose metabolism to protect against energy failure and oxidative stress but failed to evade other derangements, such as the distortion of glutamine synthesis, leading to a disturbed intercellular metabolic homeostasis and increased risk of manganese-induced neuronal energy failure.
A selective energy failure in cultured neurons was reflected by a rapid decrease of ATP and a dramatic depletion of PCr. Astrocytes were able to restore initially reduced ATP levels, consistent with previous results (Hazell et al., 1999) . Interestingly, when neurons were cocultivated with astrocytes, the decrease of PCr was even higher than the theoretical intermediate between the individual cell types. Whereas neurons were not able to increase their glycolytic activity, astrocytes showed stimulated anaerobic metabolism of external [1-13 C]glucose (with NAD + regeneration by subsequent lactate syn-thesis) that enabled, at least in part, cytosolic ATP synthesis. Unlike [3-13 C]lactate synthesis, changes in the total amount of lactate were not significant in manganese-treated astrocytes or neurons, as observed earlier (Hazell et al., 1999) . The analysis of the percentage 13 Cenrichments in [3-13 C]lactate (i.e., the selective changes in de novo synthesized [3-13 C]lactate derived from the pyruvate pool of glycolytic origin compared with exogenous substrates other than [1-13 C]glucose), however, directly reflects cell-specific changes in glycolytic activity. Our results are consistent with increased lactate in brain tissue in parallel with an ATP depletion after striatal injection of MnCl 2 (Brouillet et al., 1993) , but give supplementary evidence for a cell-specific occurrence of both features. Nevertheless, brain energy production depends almost exclusively on mitochondrial glucose oxidation. Pyruvate dehydrogenase, transforming [1-13 C]glucose into [2-13 C]acetyl-CoA and hence into the TCA-cycle intermediate [4-13 C]␣-ketoglutarate, is active in both neurons and astrocytes and plays the dominant role in regulation of oxidation and mitochondrial energy production in the brain. Only in astrocytes can [1-13 C]glucose be transformed into [2-13 C]␣-ketoglutarate via the astrocyte-specific PC, the main anaplerotic enzyme in the brain (Shank et al., 1985) . 13 C-NMR analysis showed a dramatic inhibition of neuronal oxidative glucose metabolism via PDH, decreased 13 C-enrichment in acetyl-CoA entering the TCA cycle and reduced TCA cycle FIG. 9. Short-term effects of manganese in neurons and astrocytes. The changes in 13 C-labeled metabolites related to energy metabolism (A and B) and of metabolites related to mitochondrial integrity and antioxidant defense (C) after 12-h and 5-d treatment of astrocytes with manganese, respectively, were calculated from 31 P and 13 C-NMR spectra. Changes in ATP, PCr, [1-13 C]glucose, taurine, and succinate are based on their absolute concentrations; changes in [4- 13 C] glutamate and [2- 13 C] acetyl-CoA as well as in [4- 13 C] glutamine and in the ratio of 13 C-4/ 13 C-2 in glutamate and glutamine are based on their percentage 13 C-enrichments, and changes in glutathione and citrate are based on their 13 C-signal intensity in 13 C-NMR spectra. Values are given as percentage of control and represent means ± SD of four to six individual experiments. Data between all experimental groups were analyzed using ANOVA and post hoc Tukey test (***P < 0.001; **P < 0.01, compared with controls; see text for differences between 12-h and 5-d treatment). Asp, aspartate; Gln, glutamine; Glu, glutamate; GSH, glutathione; EDTA, ethylenediamine tetraacetic acid.
turnover, leading to deterioration of the neuronal energy state and impaired de novo synthesis of neurotransmitter amino acids (i.e., glutamate, aspartate, and GABA). In contrast, in astrocytes a strongly stimulated uptake and oxidation of [1-13 C]glucose through PDH, which coincided with increased 13 C-enrichment in acetyl-CoA and amplified 13 C-cycling ratio within the TCA cycle, seems to be the most prominent mechanism to avoid manganese-induced cellular energy failure. Our results suggest that limited availability of external glucose for mitochondrial metabolism leads to an inability of neurons to antagonize an energy depletion by oxidative metabolism, and that limited flux through PDH further aggravates the energy failure.
Since astrocytes sequester manganese (Aschner et al., 1992; Tholey et al., 1990; Wedler et al., 1989) , it has been suggested that these cells are likely initial targets of manganese toxicity (Henriksson and Tjalve, 2000; Spranger et al., 1998) . The prevention of energy failure by stimulated glucose oxidation and glycolytic activity in manganese-treated astrocytes does not necessarily contradict this hypothesis. The accumulation of succinate and citrate in all cell types suggests an inhibition of intermediary metabolism at the level of succinate dehydrogenase (Hietanen et al., 1981) and of aconitase (Zheng et al., 1989) . Similar to a direct effect of manganese on oxidative phosphorylation (Gavin et al., 1992) and complex I activity (Galvani et al., 1995) , an inhibition of these TCA cycle enzymes ultimately leads to decreased availability of reduced equivalents for oxidative phosphorylation and hence to an energy deficit. Interestingly, accumulation of succinate and citrate as well as the decrease of [ 13 C]acetyl-CoA entering the TCA cycle were highest when neurons were cocultivated with astrocytes. Therefore, manganese-induced changes in astrocytes may either modify a primary neuronal injury or induce secondarily neuronal dysfunction.
Besides neuronal glucose oxidation, neurons rely on the supply of substrates synthesized and released by astrocytes (Hertz et al., 1999) . Several in vitro studies (Pellerin et al., 1998; Waagepetersen et al., 1998; Zwingmann et al., 2000) have proposed an astrocyte-neuron "lactate shuttle" for the maintenance of neuronal energy and neurotransmitter metabolism. The different effects of manganese on the percentage 13 C-enrichments in intraand extracellular lactate are consistent with the presence of metabolically compartmentalized pools of cytosolic pyruvate in neurons and astrocytes (Bouzier et al., 1998; Cruz et al., 2001; Zwingmann et al., 2001) , which may be modified under pathological conditions. Compared with pure astrocytes, however, manganese-induced stimulation of glycolytic flux was less after cocultivation with neurons, and in view of the decreased 13 C-enrichment in extracellular lactate, astrocytic ability to regulate glycolytic synthesis of releasable lactate seems to be un-coupled from substrate requirements in manganesetreated neurons when cocultivated with astrocytes. Nevertheless, the normal rate of glycolysis in astrocytes does not exceed approximately 15 nmol glucose·min· −1 mg −1 protein (Marrif and Juurlink 1999) , a value almost reached in our manganese-treated cocultures, and neuronal oxidative metabolism cannot rise more rapidly than dictated by the subtype LDH5 isoenzyme prevailing in astrocytes (Gjedde and Marrett, 2001) . Although the support of neuronal function with lactate as a sole energy substrate has been reported in several encephalopathies (Nemoto et al., 1974; Schurr et al., 1997) , astrocyte-derived lactate may be insufficient to restore the energy deficit in neurons suffering from impaired oxidative metabolism of glucose.
Several positron emission tomography studies have shown that neurons regulate their oxidative metabolism using their own rather than astrocytic-generated pyruvate (Gjedde and Marrett, 2001) . Since neurons lack anaplerotic activity, however, they cannot maintain de novo synthesis of neurotransmitter amino acids and permanently require new carbons from astrocytes. In contrast to lactate, glial PC activity and glutamine synthesis are significant in brain interplay between glutamatergic action and glucose metabolism (Gruetter et al., 2001) . Manganese may play an important role in glial metabolism (Tholey et al., 1987) owing to the localization of PC and GS (Norenberg and Martinez-Hernandez, 1979) in these cells, with both metalloenzymes requiring manganese.
In astrocytes, manganese treatment resulted in abnormal stimulation of PDH versus PC activity and intracellular accumulation of de novo synthesized [4-13 C]glutamate. From the manganese-induced accumulation of glutamate in these cells, one might expect an increased flux through GS, but glutamine synthesis remained unchanged and even decreased after brief exposure despite a more than fivefold elevation of [4-13 C]glutamate. Despite cocultivation of astrocytes with neurons stimulating both synthesis and release of glutamine, which is consistent with increased GS messenger RNA and activity (Mearow et al., 1990; Wu et al., 1988) , de novo synthesized glutamine was hardly detectable after manganese treatment. These findings are in disagreement with reports of increased GS expression in manganese-exposed rat brain (Zheng et al. 1999 ) and cultured astrocytes (Chen and Liao, 2002) . The complexity of GS regulation provides several explanations for this paradoxical effect. For example, changes in the synthesis rate may not necessarily coincide with changes in protein expression. In addition, depending on the concentration, manganese may both activate and inhibit GS, and maximal GS activity occurs at a defined cation/ATP ratio (Tholey et al. 1987) . Although the distortion of glutamine synthesis may conserve astrocytic energy consumption, this may have profound consequences for the normal metabolic balance between astrocytes and neurons. First, as glutamine synthesized in astrocytes serves as an important neuronal energy substrate and precursor of glutamate (Hertz et al., 1999) , a limited supply of glutamine to neurons would additionally impair neuronal oxidative metabolism and deplete the neurotransmitter pool of glutamate as well. Second, the inability to convert glutamate to glutamine may represent one mechanism contributing to impaired reuptake of glutamate into astrocytes after manganese exposure (Hazell and Norenberg, 1997) , making neuronal cells more prone to excitotoxicity. An impaired reuptake of neuronal glutamate is consistent with the relative greater decrease of glutamine metabolically derived from [4-13 C]glutamate (PDH) compared with that derived from [2-13 C]glutamate formed exclusively via astrocytic PC. Furthermore, the reduction in the total amount of [4- 13 C] glutamine was higher than the increase of [4-13 C]glutamate (23.1 vs. 11.05 nmol/mg protein), further indicating impaired trafficking via the glutamine-glutamate cycle. Similarly, the accumulation of [2-13 C]GABA in cocultures, which is metabolically derived from neuronal [4-13 C]glutamate rather than from astrocytic glutamine, may be the result of impaired reuptake via the GABA shunt, an important pathway for the reentry of GABA into the TCA cycle (Hassel et al., 1998) .
Several studies using various paradigms of oxidative stress have shown that reactive oxygen species can inactivate GS (Brand et al., 1999; Minana et al., 1997; Oliver et al., 1990; Schor, 1988) , which would be consistent with manganese-induced oxidative stress involving formation of reactive oxygen species and free radicals (Chen and Liao, 2002; Spranger et al., 1998) . The reduced label incorporation from [1-13 C]glucose into the [4-13 C]glutamate residue of neuronal glutathione, a major intracellular antioxidant (Dringen, 2000) , after prolonged manganese exposure indicates a likely impairment of the neuronal antioxidant system in parallel with energy deficits. Astrocytes, in contrast, showed a rapid, more than 10-fold increase in the synthesis of glutathione from [1-13 C]glucose, which likely reflects a protective response against formation of reactive oxygen species. The higher ratio of double-to mono-labeled 13 C-4 in the glutamate residue of glutathione compared with glutamate revealed glutathione synthesis occurring consecutively to manganese-induced stimulation of PDH (i.e., after the carbon skeleton of glutamate has passed several TCA cycle turns). However, the initial dramatic stimulation of PDH activity and hence glutathione synthesis slowed down in astrocytes, and the even greater decrease of [2- 13 C] acetyl-CoA and [ 13 C]glutathione in cocultures compared to pure neurons, together with the deterioration of the cellular energy state, suggests a failure of astrocytes to maintain energy metabolism and antioxi-dant defense mechanisms after sustained manganese exposure. Interestingly, manganese exerted a similar effect on the concentration of taurine in neurons and cocultures, which, like glutathione, is a free radical scavenger and can protect against excitotoxicity (Saransaari and Oja, 2000) and plays an important role as an organic osmolyte in astrocytes (Olson and Li, 2000) . Interestingly, hypotaurine, the precursor for taurine, and myo-inositol, which both participate in cell volume regulation in astrocytes (Brand et al., 1993; Isaacks et al., 1999) , were strongly decreased in these cells when cocultivated with neurons and may reflect effects of manganese on the control of ion and volume regulation in astrocytes in the presence of neurons.
In this study, a selective impairment of neuronal oxidative metabolism of glucose and astrocytic substrates was shown by 13 C-isotopomer analysis of [1-13 C]glucose metabolism, which labels TCA cycle metabolites in different carbon positions depending on the contribution of cell-specific and intercellular pathways. We have presented data indicating that manganese produces differential changes in glucose utilization in astrocytes and neurons that may play an important role in determining the relative vulnerability of neuronal cells in manganese neurotoxicity (Fig. 10) . Inhibition of neuronal PDH impedes the ability of neurons to compensate for mitochondrial dysfunction by raising oxidative glucose metabolism and further aggravates neuronal energy failure.
FIG. 10.
Relation between cell-specific glucose metabolism and neuronal vulnerability in manganese neurotoxicity. Mitochondrial dysfunction in neurons (1; possibly related to oxidative stressmediated changes) is associated with impaired cellular energy metabolism. Such abnormalities may lead to energy failure (2). Inhibition of neuronal pyruvate dehydrogenase (PDH; 3) hinders the ability of neurons to compensate for mitochondrial dysfunction by increasing oxidative glucose metabolism and further aggravates neuronal energy failure. In addition, metabolic changes in astrocytic glucose metabolism, such as the inhibition of glutamine synthesis, may cause a homeostatic dysequilibrium between neurons and astrocytes (4), leading to further potentiation of the primary neuronal dysfunction, and conceivably activation of an excitotoxic state (5).
Although astrocytes maintain their normal energy state and antioxidant mechanisms by upregulation of glucose metabolism through increased glycolysis, PDH and Krebs cycle activity, astrocytic dysfunction in the presence of neurons (e.g., reduced glutamine synthesis) may cause a homeostatic dysequilibrium between both cell types, leading to further potentiation of the primary neuronal derangement and, conceivably, the eventual development of an excitotoxic state. These self-protective metabolic responses may also facilitate astrocyte survival and the development of reactive gliosis in the face of concomitant neuronal dysfunction. Our results provide a cell type-specific basis for some possible mechanisms associated with energy failure in manganese neurotoxicity. Future studies are necessary to characterize the sequence of metabolic events. Further NMR investigations using 13 C-labeled substrates involved in energy and neurotransmitter metabolism as well as the cellular antioxidant defense system, combined with in vitro, ex vivo, and in vivo approaches, may provide additional information concerning the primary basis and significance of energy failure in manganese neurotoxicity.
